Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEMEYA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of Janus kinase 1 (JAK1), modulating the JAK-STAT signaling pathway to reduce pro-inflammatory cytokine production.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
FDA-approved: Treatment of moderate to severe rheumatoid arthritis in adult patients with an inadequate response to methotrexate.,Off-label: Not typically used off-label due to limited data.
Prevention of pregnancy
KEMEYA (zoledronic acid) 5 mg intravenously once yearly for osteoporosis. For Paget disease, 5 mg intravenously as a single dose.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life: 12-15 hours; Clinical context: allows twice-daily dosing; prolonged in renal impairment (up to 24-30 hours in Cr Cl <30 m L/min)
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Forms inactive metabolites.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~70% as unchanged drug; Fecal: ~20% as metabolites; Biliary: <10%
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
High: ~95% bound to albumin and alpha-1-acid glycoprotein
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Vd: 3-5 L/kg; indicates extensive tissue distribution
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 80-90%
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
Contraindicated if Cr Cl <35 m L/min; for osteoporosis, not recommended if Cr Cl <35 m L/min. No dose adjustment needed for Cr Cl >=35 m L/min.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
No specific dose adjustment required for hepatic impairment; caution in severe hepatic impairment due to limited data.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy not established in children; no approved pediatric dosing.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific dose adjustment for elderly; monitor renal function as age-related decline in Cr Cl may necessitate avoidance if Cr Cl <35 m L/min.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, AND THROMBOSIS. Patients treated with KEMEYA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants. If a serious infection develops, interrupt KEMEYA until the infection is controlled. Reported infections include active tuberculosis, invasive fungal infections, and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been observed. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have been reported. Consider risks vs benefits before initiating therapy.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Risk of serious infections, including tuberculosis and invasive fungal infections.,Avoid use in patients with active infections.,Monitor for signs and symptoms of infection during treatment.,Risk of thrombosis: Use with caution in patients with risk factors for thrombosis.,Risk of malignancy, particularly lymphoma.,Hepatotoxicity: Monitor liver enzymes regularly.,Cytopenias: Monitor complete blood counts at baseline and periodically.,Gastrointestinal perforations have been reported; monitor for abdominal pain.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Hypersensitivity to the active substance or any excipients.,Active serious infections, including localized infections.,Known active tuberculosis.,Severe hepatic impairment (Child-Pugh C).,Pregnancy (based on animal studies showing fetal harm).
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions. Grapefruit product interactions are not clinically significant. Avoid estrogen-containing foods (e.g., soy supplements) as they may reduce efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
KEMEYA is contraindicated in pregnancy. Based on animal studies and its mechanism of action, KEMEYA may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Teratogenic effects have been observed in animal reproduction studies at doses below the recommended human dose. In particular, exposure during the first trimester is associated with major congenital malformations, including neural tube defects, craniofacial abnormalities, and cardiovascular defects. During the second and third trimesters, fetal growth restriction and oligohydramnios may occur.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
It is not known whether KEMEYA is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from KEMEYA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The milk-to-plasma (M/P) ratio has not been determined for KEMEYA.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Due to the risk of fetal harm, KEMEYA is contraindicated in pregnancy, and no dose adjustments are recommended. If inadvertent exposure occurs during pregnancy, the drug should be discontinued immediately. The pharmacokinetics of KEMEYA in pregnant women have not been studied, and thus no specific dosing guidelines for pregnancy exist.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
KEMEYA (letrozole) is an aromatase inhibitor used for hormone receptor-positive breast cancer. Monitor for bone mineral density loss and consider bisphosphonates. Not effective in estrogen receptor-negative tumors. Avoid in premenopausal women without concurrent ovarian suppression. Dose adjustment needed in severe hepatic impairment (Child-Pugh C).
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take exactly as prescribed, usually once daily without regard to meals.,Report any new bone pain, joint stiffness, or fractures promptly.,Use effective non-hormonal contraception if premenopausal; letrozole can cause fetal harm.,May cause hot flashes, fatigue, and night sweats; these are not dangerous.,Do not take estrogen-containing medications or supplements while on letrozole.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEMEYA vs ALYACEN 7/7/7, answered by our medical review team.
KEMEYA is a Oral Contraceptive that works by Selective inhibitor of Janus kinase 1 (JAK1), modulating the JAK-STAT signaling pathway to reduce pro-inflammatory cytokine production.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEMEYA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEMEYA is: KEMEYA (zoledronic acid) 5 mg intravenously once yearly for osteoporosis. For Paget disease, 5 mg intravenously as a single dose.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEMEYA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEMEYA is classified as Category C. KEMEYA is contraindicated in pregnancy. Based on animal studies and its mechanism of action, KEMEYA may cause fetal harm when administered to a pregnant woman. There are no adequat. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.